Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
2.701
Zitationen
25
Autoren
2020
Jahr
Abstract
The safety and immunogenicity data from this U.S. phase 1 trial of two vaccine candidates in younger and older adults, added to earlier interim safety and immunogenicity data regarding BNT162b1 in younger adults from trials in Germany and the United States, support the selection of BNT162b2 for advancement to a pivotal phase 2-3 safety and efficacy evaluation. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Ähnliche Arbeiten
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
2020 · 51.533 Zit.
Clinical Characteristics of Coronavirus Disease 2019 in China
2020 · 31.032 Zit.
A Novel Coronavirus from Patients with Pneumonia in China, 2019
2020 · 30.157 Zit.
A pneumonia outbreak associated with a new coronavirus of probable bat origin
2020 · 23.165 Zit.
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
2020 · 22.609 Zit.
Autoren
- Edward E. Walsh
- Robert W. Frenck
- Ann R. Falsey
- Nicholas Kitchin
- Judith Absalon
- Alejandra Gurtman
- Stephen Lockhart
- Kathleen M. Neuzil
- Mark J. Mulligan
- Ruth Bailey
- Kena A. Swanson
- Ping Li
- Kenneth Koury
- Warren V. Kalina
- David Cooper
- Camila R. Fontes-Garfias
- Pei‐Yong Shi
- Özlem Türeci
- Kristin R. Tompkins
- Kirsten E. Lyke
- Vanessa Raabe
- Philip R. Dormitzer
- Kathrin U. Jansen
- Uğur Şahin
- William C. Gruber